Sun Pharma announces Late-Breaking Phase 2 data showing potential of ILUMYA (tildrakizumab-asmn)
The drug has been designed to improve joint and skin symptoms of Psoriatic Arthritis. Over 71 per cent of patients treated with…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
DRL to sell neurology branded products to Upsher-Smith Laboratories
Dr Reddy’s would sell its US and select territory rights for ZEMBRACE SYMTOUCH and TOSYMRATM, which are commercialized through its…
‘The Future of Supply Chain Management’ by OPPI
The Organisation of Pharmaceutical Producers of India (OPPI), in collaboration with Indian Pharmaceutical Alliance and Indian Drug…
OPPI to host an event on ‘The Future of Supply Chain Management’
The event endeavours to explore the challenges of supply chain management through discussions on manufacturing, warehousing,…
Wockhardt’s bioequivalence centre at Aurangabad receives zero observations from US FDA
During the inspection, bioanalytical and quality systems of bioequivalence studies of Tamsulosin 0.4 mg capsules and Metoprolol ER…
Neelikon conferred with the ‘SME Elite 50’ award
The award is a recognition as one of the Best Entrepreneur in the SME sector in India
Sobi buys rare-disease drug emapalumab, zooms in on hematology and immunology
The drug-maker said that it would buy a newly established company owning the drug candidate for the treatment of primary…
Catalyst Pharma sues FDA over approval of cheaper rival drug
The lawsuit alleges that the approval of Ruzurgi, a rival drug from privately held Jacobus Pharma, violated provisions of FDA…
Oral Novo Nordisk diabetes drug poses no more heart risk than placebo: study
Patients with type 2 diabetics and either heart disease who received the drug semaglutide in pill form had a combined rate of…
New psoriasis drug study yields positive results: Dr Reddy’s
According to a press release from the city-based drug-maker, the detailed safety and efficacy data from the study would be…